Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radiotherapy + temozolomide + doxorubicin
- Development stage
- Unknown
- Lead developer
- Aston University
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- External Beam Radiation, Oral, Intravenous
01
Overview
A combination treatment regimen for glioblastoma multiforme (GBM) that includes radiation therapy plus two chemotherapeutic agents. Radiotherapy delivers targeted radiation to destroy cancer cells, temozolomide is an oral alkylating agent that crosses the blood-brain barrier and causes DNA damage, and doxorubicin is an anthracycline antibiotic that stabilizes topoisomerase II and prevents DNA replication.
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on radiotherapy + temozolomide + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radiotherapy + temozolomide + doxorubicin.